Regina W. Hofland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Regina W. Hofland has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Aik W. J. Bossink
B Department of Respiratory Medicine, Diakonessenhuis , Utrecht , The Netherlands
3 shared publicationsJan-Willem J. Lammers
A Department of Respiratory Medicine , University Medical Centre Utrecht, Utrecht University , Utrecht , The Netherlands
3 shared publicationsSteven F. T. Thijsen
E Department of Medical Microbiology and Immunology , Diakonessenhuis , Utrecht , The Netherlands
3 shared publicationsAnne S. R. van Lindert
B Department of Respiratory Medicine , University Medical Centre Utrecht , Utrecht , The Netherlands
1 shared publicationBente Aalbers
University Medical Center, Utrecht, Netherlands
1 shared publication- Bert Arets
Department of Psychiatry and Neuropsychology, Mental Health and Neuroscience Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, the Netherlands
1 shared publication
Latest Publications
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting
Introduction: Recently, a new CFTR modulator (elexacaftor/tezacaftor/ivacaftor, TrikaftaTM) has been positively evaluated in a clinical trial for patients with cystic fibrosis (pwCF) and is awaiting approval to the European market. Meanwhile, it can be requested for patients in poor condition (compassionate use). Aim: The aim of this study is to evaluate the clinical response of TrikaftaTM in pwCF in a compassionate use setting. Methods: pwCF who start TrikaftaTM compassionate use are prospectively followed with assessment of spirometry, BMI, chest CT, CFQ-R and sweat chloride concentration (SCC) before start and after 3 months. Furthermore, spirometry and BMI are repeated after 1 and 6 months. Results: At this moment, 13 pwCF are eligible for this evaluation, 6 with F508del homozygous and 7 with F508del/minimal function mutation. As inclusion and follow-up is still continuing, we only can report baseline and preliminary follow-up data thus far. Mean age at start was 33.5 years (range 19-55), with a mean ppFEV1 of 28.6 (range 19-38), mean SCC of 81.3 mmol/l (range 17-111) and mean BMI of 21.4 (range 14.1-28.7). After 1 month, mean change in ppFEV1 (n=11) was +3.82 (p= 0.009). Mean change in BMI (n=11) was +0.45 (p=0.025). After 3 months, mean change in SCC (n=4) was -50.3 (p=0.003), together with significant improvement in CT and CFQ-R results. Conclusion: Although preliminary and pending results, pwCF thus far experience relevant clinical benefit to treatment with TrikaftaTM in a compassionate use setting. More follow-up data will follow next months.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting
Introduction: Recently, a new CFTR modulator (elexacaftor/tezacaftor/ivacaftor, TrikaftaTM) has been positively evaluated in a clinical trial for patients with cystic fibrosis (pwCF) and is awaiting approval to the European market. Meanwhile, it can be requested for patients in poor condition (compassionate use). Aim: The aim of this study is to evaluate the clinical response of TrikaftaTM in pwCF in a compassionate use setting. Methods: pwCF who start TrikaftaTM compassionate use are prospectively followed with assessment of spirometry, BMI, chest CT, CFQ-R and sweat chloride concentration (SCC) before start and after 3 months. Furthermore, spirometry and BMI are repeated after 1 and 6 months. Results: At this moment, 13 pwCF are eligible for this evaluation, 6 with F508del homozygous and 7 with F508del/minimal function mutation. As inclusion and follow-up is still continuing, we only can report baseline and preliminary follow-up data thus far. Mean age at start was 33.5 years (range 19-55), with a mean ppFEV1 of 28.6 (range 19-38), mean SCC of 81.3 mmol/l (range 17-111) and mean BMI of 21.4 (range 14.1-28.7). After 1 month, mean change in ppFEV1 (n=11) was +3.82 (p= 0.009). Mean change in BMI (n=11) was +0.45 (p=0.025). After 3 months, mean change in SCC (n=4) was -50.3 (p=0.003), together with significant improvement in CT and CFQ-R results. Conclusion: Although preliminary and pending results, pwCF thus far experience relevant clinical benefit to treatment with TrikaftaTM in a compassionate use setting. More follow-up data will follow next months.
- 8 January 2018
- Published by Taylor & Francis in Infectious Diseases
- Vol. 50 (6) , 479-482
QuantiFERON-plus does not discriminate between active and latent tuberculosis
(2018). QuantiFERON-plus does not discriminate between active and latent tuberculosis. Infectious Diseases: Vol. 50, No. 6, pp. 479-482.
- 8 January 2018
- Published by Taylor & Francis in Infectious Diseases
- Vol. 50 (6) , 479-482
QuantiFERON-plus does not discriminate between active and latent tuberculosis
(2018). QuantiFERON-plus does not discriminate between active and latent tuberculosis. Infectious Diseases: Vol. 50, No. 6, pp. 479-482.
- Open Access
- 26 December 2016
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (5) , 347-355
Positive predictive value of ELISpot in BAL and pleural fluid from patients with suspected pulmonary tuberculosis
The aim of this study was to evaluate the positive predictive value (PPV) of ELISpot in bronchoalveolar lavage (BAL) and pleural fluid for the diagnosis of active tuberculosis (TB) in real-life clinical practice, together with the added value of a cut-off >1.0 for the ratio between the extra-sanguineous and systemic interferon-gamma responses in positive samples.
- 26 December 2016
- Published by Taylor & Francis in Infectious Diseases
- Vol. 49 (5) , 347-355
Open AccessPositive predictive value of ELISpot in BAL and pleural fluid from patients with suspected pulmonary tuberculosis
The aim of this study was to evaluate the positive predictive value (PPV) of ELISpot in bronchoalveolar lavage (BAL) and pleural fluid for the diagnosis of active tuberculosis (TB) in real-life clinical practice, together with the added value of a cut-off >1.0 for the ratio between the extra-sanguineous and systemic interferon-gamma responses in positive samples.
- 1 February 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (2) , 504-505
Pleural Fluid and Tuberculosis: Are All Interferon Gamma Release Assays Equal?
- 1 February 2016
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 54 (2) , 504-505
Pleural Fluid and Tuberculosis: Are All Interferon Gamma Release Assays Equal?